Statins and risk of cholangiocarcinoma: A systematic review and meta-analysis

Karn Wijarnpreecha, Elizabeth S. Aby, Hassan Ghoz, Wisit Cheungpasitporn, Frank J. Lukens, Denise M. Harnois, Patompong Ungprasert

Research output: Contribution to journalArticlepeer-review


Background & Aims: The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together. Methods: A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird. Results: A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I2 96%). Conclusions: The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.

Original languageEnglish (US)
Pages (from-to)629-635
Number of pages7
JournalJournal of Gastrointestinal and Liver Diseases
Issue number4
StatePublished - 2020


  • Bile duct cancer
  • Biliary tract cancer
  • Cholangiocarcinoma
  • Meta-analysis
  • Statins

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Statins and risk of cholangiocarcinoma: A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this